135 related articles for article (PubMed ID: 32912664)
1. Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
Madariaga A; Garg S; Bruce JP; Thiryayi S; Mandilaras V; Rath P; Oza AM; Dhani NC; Cescon DW; Lee YC; Chen E; Wang L; Clarke B; Lheureux S
Gynecol Oncol; 2020 Nov; 159(2):539-545. PubMed ID: 32912664
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01).
Ngoi NYL; Heong V; Tang JI; Choo BA; Kumarakulasinghe NB; Lim D; Low M; Lim SE; Lim YW; Leong YH; Tseng M; Tong PSY; Ilancheran A; Low JJH; Ng J; Thian YL; Koh V; Tan DSP
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):701-711. PubMed ID: 33045316
[TBL] [Abstract][Full Text] [Related]
3.
Jeleniewicz W; Cybulski M; Nowakowski A; Stenzel-Bembenek A; Guz M; Marzec-Kotarska B; Kotarski J; Stepulak A
Anticancer Res; 2019 Apr; 39(4):1821-1827. PubMed ID: 30952722
[TBL] [Abstract][Full Text] [Related]
4. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
Shawky H; Tawfik H; Hewidy M
J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
[TBL] [Abstract][Full Text] [Related]
5. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
6. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Lorusso D; Hilpert F; González Martin A; Rau J; Ottevanger P; Greimel E; Lück HJ; Selle F; Colombo N; Kroep JR; Mirza MR; Berger R; Pardo B; Grischke EM; Berton-Rigaud D; Martinez-Garcia J; Vergote I; Redondo A; Cardona A; Bastière-Truchot L; du Bois A; Kurzeder C;
Int J Gynecol Cancer; 2019 Sep; 29(7):1141-1147. PubMed ID: 31420414
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
9. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL; Handley KF; Burger R; Molin GZD; Stagg R; Sood AK; Moore KN
Gynecol Oncol; 2020 May; 157(2):386-391. PubMed ID: 32037195
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Han Y; Huang H; Xiao Z; Zhang W; Cao Y; Qu L; Shou C
PLoS One; 2012; 7(12):e52745. PubMed ID: 23300757
[TBL] [Abstract][Full Text] [Related]
11. The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes.
Seborova K; Kloudova-Spalenkova A; Koucka K; Holy P; Ehrlichova M; Wang C; Ojima I; Voleska I; Daniel P; Balusikova K; Jelinek M; Kovar J; Rob L; Hruda M; Mrhalova M; Soucek P; Vaclavikova R
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008510
[TBL] [Abstract][Full Text] [Related]
12. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
O'Malley DM; Richardson DL; Rheaume PS; Salani R; Eisenhauer EL; McCann GA; Fowler JM; Copeland LJ; Cohn DE; Backes FJ
Gynecol Oncol; 2011 May; 121(2):269-72. PubMed ID: 21315428
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
Grisham RN; Moore KN; Gordon MS; Harb W; Cody G; Halpenny DF; Makker V; Aghajanian CA
Clin Cancer Res; 2018 Nov; 24(22):5525-5533. PubMed ID: 29844129
[No Abstract] [Full Text] [Related]
15. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
16. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
17. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
18. Resensitizing Paclitaxel-Resistant Ovarian Cancer via Targeting Lipid Metabolism Key Enzymes CPT1A, SCD and FASN.
Ma Q; Liu Z; Wang T; Zhao P; Liu M; Wang Y; Zhao W; Yuan Y; Li S
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003694
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
